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Cerebrospinal fluid (CSF) tau, tau phosphorylated
at threonine 181 (ptau), and Ab42 are established
biomarkers for Alzheimer’s disease (AD) and have
been used as quantitative traits for genetic analyses.
We performed the largest genome-wide association
study for cerebrospinal fluid (CSF) tau/ptau levels256 Neuron 78, 256–268, April 24, 2013 ª2013 Elsevier Inc.published to date (n = 1,269), identifying three
genome-wide significant loci for CSF tau and ptau:
rs9877502 (p = 4.89 3 109 for tau) located at
3q28 between GEMC1 and OSTN, rs514716 (p =
1.07 3 108 and p = 3.22 3 109 for tau and ptau,
respectively), located at 9p24.2 within GLIS3 and
rs6922617 (p = 3.58 3 108 for CSF ptau) at 6p21.1
within the TREM gene cluster, a region recently
Table 1. Summary of Sample Characteristics
Knight-ADRC ADNI UW UPenn
n 501 394 323 51
Age (years);
mean ± SD
(range)
69 ± 9 (46–91) 75 ± 6.9
(55–91)
67 ± 10
(45–88)
67 ± 9
(50–86)
APOE ε4+ (%) 37 49 43 61
CDR 0 (%) 73 27 61 2
Male (%) 42 60 48 33
Ptau 64 ± 35
(17–229)
34 ± 18
(7–115)
37 ± 17
(5–83)
35 ± 24
(6–116)
Tau 355 ± 229
(85–1,624)
98 ± 57
(28–495)
77 ± 35
(27–204)
81 ± 60
(17–351)
Ab42 587 ± 247
(154–1,293)
170 ± 56
(53–300)
216 ± 73
(64–366)
177 ± 59
(78–298)
Age at lumbar puncture (LP), percentage of males, percentage of APOE4
allele carriers, and clinical dementia rating (CDR) at LP date for each sam-
ple. For each phenotype, the mean in pg/ml with the standard deviation
and range is shown. Charles F. and Joanne Knight Alzheimer’s Disease
ResearchCenter at University ofWashington (Knight-ADRC), Alzheimer’s
Disease Neuroimaging Initiative (ADNI), and for the University of
Washington, Seattle (UW). Cerebrospinal fluid (CSF); case-control (CC).
See also Table S1.
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GWAS for CSF Tau Levelsreported to harbor rare variants that increase AD risk.
In independent data sets, rs9877502 showed a
strong association with risk for AD, tangle pathology,
and global cognitive decline (p = 2.67 3 104, 0.039,
4.86 3 105, respectively) illustrating how this endo-
phenotype-based approach can be used to identify
new AD risk loci.
INTRODUCTION
AD is neuropathologically characterized by the presence of
extracellular Ab plaques and intracellular aggregates of hyper-
phosphorylated tau in the brain (Hardy and Selkoe, 2002). CSF
Ab42 and tau levels have emerged as useful biomarkers for dis-
ease and endophenotypes for genetic studies of AD. CSF tau
and tau phosphorylated at threonine 181 (ptau) are higher in
AD cases compared with nondemented elderly controls (Shoji
et al., 1998; Kawarabayashi et al., 2001; Strozyk et al., 2003;
Sunderland et al., 2003; Hampel et al., 2004; Jia et al., 2005;
Schoonenboom et al., 2005; Welge et al., 2009). It has been
shown that genetic variants that increase risk for AD modify
CSF Ab42 and tau levels, including pathogenic mutations in
APP, PSEN1, and PSEN2, and the common variants in APOE
(Kauwe et al., 2007, 2008, 2009; Ringman et al., 2008; Cruchaga
et al., 2010). CSF ptau levels correlate with the number of neuro-
fibrillary tangles and the load of hyperphosphorylated tau pre-
sent in the brain (Buerger et al., 2006). Elevated CSF ptau levels
are correlated with neuronal loss and predict cognitive decline
and conversion to AD in subjects with mild cognitive impairment
(de Leon et al., 2004; Buerger et al., 2006; Andersson et al.,
2007). Enigmatically, CSF tau levels are normal or low in other
tauopathies such as progressive supranuclear palsy, so the
precise relationship between the burden of tau pathology as
well as the extent of neurodegeneration and the levels of CSF
tau remain to be fully clarified (Hu et al., 2011). This notwith-
standing, CSF tau levels may be a useful marker to identify
genetic variants implicated not only with risk for Alzheimer’s
disease but also age at onset (Kauwe et al., 2008) or rate of
progression (Shoji et al., 1998; Cruchaga et al., 2010). Previous
GWAS for CSF tau and ptau levels (Han et al., 2010; Kim et al.,
2011) have been conducted in much smaller samples and have
shown robust association with markers on chromosome 19
surrounding APOE but failed to detect additional genome-wide
significant associations. We have conducted a genome-wide
association study (GWAS) for CSF tau and ptau using a sample
that is more than three times the size of previous studies and
have successfully detected loci that show novel genome-wide
significant association signals.
RESULTS
Variability in CSF Tau and Ptau Levels Explained
by Common Variants
Before performing any analysis, we performed stringent quality
control (QC) in both the genotype and the phenotype data. For
the phenotype data we confirmed that the tau and ptau level
followed a normal distribution after log transformation. We alsoperformed a stepwise regression analysis to identify the covari-
ates showing a significant association with these endopheno-
types. We performed a GWAS on 1,269 unrelated individuals
recruited through the Knight-ADRC at Washington University,
the Alzheimer’s Disease Neuroimaging Initiative, a biomarker
Consortium of Alzheimer Disease Centers coordinated by
University of Washington and the University of Pennsylvania
(Table 1 and see Table S1 available online). While there are differ-
ences in the absolute levels of the biomarker measurements
between the different studies that likely reflect differences in
the methods used for quantification (regular ELISA versus
Luminex), both methods measure the same analytes but yield
different absolute levels. In addition, CSF ptau and tau levels
in the different studies show similar characteristics. CSF ptau
and tau levels show a 10- to 17-fold difference in each data
set, are normally distributed after log transformation, and have
similar covariates in each data set (see statistical analyses).
To maximize our statistical power we performed a single-
stage GWAS with our combined sample (Dube´ et al., 2007;
Rohlfs et al., 2007; Kraft and Cox, 2008). The sample includes
687 elderly nondemented individuals and 591 individuals with a
clinical diagnosis of AD (Tables 1 and S1). We used linear regres-
sion to test the additive genetic model of each single nucleotide
polymorphism (SNP) for association with CSF biomarker levels
after adjustment for age, gender, site, and the three principal
component factors from population stratification analysis. A total
of 5,815,690 imputed and genotyped SNPs were included in
these analyses. The inclusion of clinical dementia rating (CDR)
or case/control status did not change the results significantly.
No evidence of systematic inflation of p values was found (l =
1.003 for ptau, and 1.009 for tau). To estimate the proportion
of variance in CSF tau and ptau levels explained by genetic var-
iants we used a genome-partitioning analysis (Yang et al., 2011).Neuron 78, 256–268, April 24, 2013 ª2013 Elsevier Inc. 257
Table 2. Genome-wide Significant SNPs for CSF Tau and Ptau
CHR SNP MAF Closest Gene SNP Type/Location Tau Ptau Ab42 SNP Type
19 rs769449 0.190 APOE Intron 1.95 3 1016 2.56 3 1018 9.02 3 1047 Imputed
19 rs12972970 0.193 PVRL2 Intron 8.24 3 1016 1.28 3 1015 3.74 3 1040 Imputed
19 rs34342646 0.193 PVRL2 Intron 5.54 3 1016 1.17 3 1015 4.17 3 1040 Imputed
19 rs34404554 0.208 TOMM40 Intron 3.58 3 1016 1.33 3 1016 1.01 3 1039 Imputed
19 rs11556505 0.210 TOMM40 Synonymous 3.48 3 1016 1.68 3 1016 1.06 3 1039 Imputed
19 rs2075650 0.213 TOMM40 Intron 4.28 3 1016 5.81 3 1016 2.21 3 1039 Typed
19 rs71352238 0.201 TOMM40 Intergenic 1.78 3 1016 2.46 3 1016 5.68 3 1039 Imputed
19 rs12972156 0.187 PVRL2 Intron 3.03 3 1015 2.31 3 1015 6.35 3 1037 Imputed
3 rs9877502 0.386 SNAR-I Intergenic 4.98 3 1009 1.68 3 1007 0.022 Imputed
3 rs1316356 0.362 SNAR-I Intergenic 2.80 3 1007 1.96 3 1007 0.102 Typed
9 rs514716 0.136 GLIS3 Intron 1.07 3 1008 3.22 3 1009 0.026 Imputed
9 rs622536 0.114 GLIS3 Intron 6.68 3 1007 4.50 3 1008 0.029 Imputed
9 rs59860681 0.114 GLIS3 Intron 6.68 3 1007 4.50 3 1008 4.66 3 103 Imputed
9 rs623295 0.114 GLIS3 Intron 6.68 3 1007 4.50 3 1008 4.66 3 103 Imputed
9 rs624290 0.114 GLIS3 Intron 6.68 3 1007 4.50 3 1008 4.66 3 103 Typed
6 rs6922617 0.064 NCR2 Intergenic 2.55 3 1005 3.58 3 1008 3.69 3 103 Typed
6 rs11966476 0.067 NCR2 Intergenic 1.59 3 1005 4.97 3 1008 3.99 3 103 Imputed
Standardized log-transformed CSF tau and ptau values were tested for association with the SNP in an additive model using PLINK, including age,
gender, site, and the third first component factors for population stratification. The table only shows the genome-wide significant SNPs or the most
significant genotypedSNPs for each locus. All novel loci that show associationwith CSF tau and/or ptau show aweak associationwith CSF Ab42 levels.
See also Tables S2, S3,S6, and S7.
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GWAS for CSF Tau LevelsApproximately 7% (ptau) and 15% (tau) of the variability in the
CSF levels of these proteins are explained by variants included
on the GWAS chip plus the imputed SNPs. In this study SNPs
in the APOE region show a genome-wide significant association
with CSF tau and ptau (Tables 2 and 3) and explain just 0.25%–
0.29% of the variability in CSF tau and ptau, suggesting that
most of the genetic variability in CSF tau and ptau levels is ex-
plained by other genetic variants.
APOE Variants Affect CSF Tau and Ptau Levels
Independently of Ab42
Prevailing hypotheses suggest that APOE ε4 exerts its patho-
genic effects through an Ab-dependent mechanism (Castellano
et al., 2011). However, several SNPs in the APOE region were
genome-wide significant with both tau and ptau (rs769449; p =
1.963 1016 and 2.563 1018, respectively; Tables 2 and 4; Fig-
ure 1). To determine whether APOE SNPs influence CSF tau and
ptau levels independently of Ab pathology, and disease status
we performed analyses including CSF Ab42 levels, or CDR as
covariates in a regression model. When clinical status was
included as a covariate the APOE SNP rs769449 was still the
most significant signal (p = 1.23 3 1012; Table 4). When CSF
Ab42 levels were included in the model we also found a strong,
but less significant, association for rs769449 with CSF ptau
levels (p = 3.223 1005). Analyses of tau follow the same pattern
(Table 4) suggesting that at least part of the tau/ptau-APOE
association is due to the underlying association of APOE
with Ab42 levels. When the sample was stratified by clinical
status, rs769449 showed a strong and similar effect size in
both cases (n = 519; Beta: 0.067; p = 3.383 106) and in controls258 Neuron 78, 256–268, April 24, 2013 ª2013 Elsevier Inc.(n = 687; Beta: 0.075, p = 1.543 106) with CSF ptau levels (Table
S2). Several studies have suggested that up to 30% of elderly
nondemented control samples meet neuropathological criteria
for AD (Price and Morris, 1999; Schneider et al., 2009). It has
also been shown that individuals with CSF Ab42 levels less
than 500 pg/ml in the Knight-ADRC-CSF, and 192 pg/ml in the
ADNI series have evidence of Ab deposition in the brain, as
detected by PET-PIB (Fagan et al., 2006; Jagust et al., 2009).
Individuals with CSF Ab42 levels below these thresholds could
be classified as preclinical AD cases with the presumption that
some evidence of fibrillar Ab deposits would be detected (Fagan
et al., 2006; Jagust et al., 2009). When we used these thresholds,
rs769449 showed a significant association with CSF tau and
ptau in both strata, although the effect size was almost two-
fold higher in individuals with high Ab42 levels (n = 416; Beta:
0.072; p = 6.58 3 105, for CSF tau levels) than in individuals
with low Ab42 levels (n = 478; Beta: 0.035; p = 1.83 3 10
2, for
CSF tau levels; Table S2). These results indicate that the residual
association of SNPs in the APOE region is not dependent on
clinical status or the presence of fibrillar Ab pathology and clearly
suggests that DNA variants in the APOE gene region influence
tau pathology independently of Ab or AD disease status.
To analyze whether there is more than one independent signal
in the APOE gene region, APOE genotype was included in
the model as a covariate (Table 4; additional figures on https://
hopecenter.wustl.edu/data/Cruchaga_Neuron_2013). The as-
sociation for the SNPs located in the APOE region was reduced
drastically (p values between 0.02 and 0.008), suggesting
that most of the association in this locus is driven by APOE
genotype.
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GWAS for CSF Tau LevelsLoci Associated with CSF Tau and Ptau Levels
Outside the APOE region, we detected genome-wide significant
association with three loci for CSF tau, ptau, or both at 3q28,
9p24.2, and 6p21.1. Several SNPs in each locus showed highly
significant p values (Figure 1). For all loci, at least one SNP was
directly genotyped (Table 2) and each of the data sets contrib-
uted to the signal, showing similar effect sizes and direction (Ta-
ble S3), suggesting that these are real signals and unlikely to be
the result of type I error.
The strongest association for CSF tau, after APOE, is
rs9877502 (p = 4.98 3 1009), located on 3q28 between
GEMC1 and OSTN and the noncoding RNA SNAR-I (Figures 1
and 2). Fifty-five intragenic SNPs located between SNAR-I
andOSTN, showed a p value lower than 9.003 1005 (additional
information on https://hopecenter.wustl.edu/data/Cruchaga_
Neuron_2013). Other genes located in this region, include IL1-
RAP, UTS2D, and CCDC50, all of which are highly expressed
in the brain. Bioinformatic analyses indicate that the most sig-
nificant SNP in this locus and 33 SNPs in linkage disequilibrium
(LD) with rs9877502 are located in transcription factor binding
sites and some of these SNPs are also part of a transcription
factor matrix, suggesting that rs9877502 or a linked variant could
influence the expression of one or more of the genes located in
this region.
Rs514716, located at 9p24.2 in an intron of GLIS3, shows
genome-wide significant association with both CSF tau and
ptau levels (Figure 2). The minor allele G (MAF = 0.136) is asso-
ciated with lower CSF tau (b = 0.071; p = 1.07 3 108) and
ptau levels (b = 0.072; p = 3.22 3 109). Seven additional
intronic SNPs show genome-wide significant association with
CSF ptau levels or p values lower than 9.00 3 1005 for CSF
tau levels (additional information on https://hopecenter.wustl.
edu/data/Cruchaga_Neuron_2013). We used the HapMap and
the 1,000 genome project data to identify all of the SNPs in link-
age disequilibrium (LD, R2 > 0.8) with rs514716. A total of nine
SNPs were identified, all of them intronic. Our bioinformatic
analysis indicated that none of these SNPs disrupt a core splice
site, but all of them are located in a conserved region.
Finally, for CSF ptau levels, several, relatively rare SNPs
(MAF = 0.06), located at 6p21.1, within the TREM gene cluster
show genome-wide significant p values (Figure 2). As in the
case of the other genome-wide signals, at least one SNP in the
region was directly genotyped (rs6922617, b = 0.094; p =
3.58 3 108; Table 2), and all of the CSF series contributed to
the association (Table S5). In this region, there was an additional
peak driven by rs6916710 (MAF = 0.39; p = 1.58 3 10-4; b =
0.034) located in intron 2 of TREML2. In a recent study, we
found a rare functional variant (R47H, rs75932628) in TREM2,
which substantially increases risk for AD (Guerreiro et al.,
2012). Based on these results, we genotyped rs75932628 in
the Knight-ADRC and ADNI series to test whether this variant
is associated with CSF levels. TREM2 R47H (rs75932628)
showed strong association with both CSF tau (MAF = 0.01; p =
6.9 3 10-4; b = 0.19) and ptau levels (p = 2.6 3 10-3; b = 0.16).
As expected the minor allele (T) of rs75932628 is associated
with higher CSF tau and ptau levels. The effect size (b) for
theR47Hvariant was twice that of rs6922617 and rs6916710 (Ta-
ble 5), while the less significant p value is explained by the lowerNeuron 78, 256–268, April 24, 2013 ª2013 Elsevier Inc. 259
Table 4. Most but Not All of the CSF Ptau Association with APOE Is Driven by Ab42 Levels
CHR SNP
Default Modela +Ab42 in the Model +CDR in the Model +APOE in the Model
Ptau Tau Ptau Tau Ptau Tau Ptau Tau
19 rs769449 2.57 3 10–18 1.95 3 10–16 3.22 3 1005 6.39 3 1006 1.23 3 10–12 1.04 3 10–10 1.29 3 1002 9.07 3 1003
19 rs34404554 1.33 3 10–16 8.24 3 10–16 2.91 3 1005 1.72 3 1006 1.87 3 10–12 3.19 3 10–10 1.43 3 1002 1.34 3 1002
19 rs11556505 1.68 3 10–16 5.54 3 10–16 3.86 3 1005 1.58 3 1006 2.83 3 10–12 3.00 3 10–10 1.77 3 1002 1.55 3 1002
19 rs71352238 2.46 3 10–16 3.58 3 10–16 5.33 3 1005 1.58 3 1006 1.13 3 10–11 2.04 3 10–10 1.37 3 1002 9.46 3 1003
19 rs2075650 5.83 3 10–16 3.48 3 10–16 8.82 3 1005 8.22 3 1007 1.01 3 10–11 3.88 3 10–10 2.24 3 1002 2.03 3 1002
19 rs34342646 1.18 3 10–15 4.28 3 10–16 9.36 3 1005 1.04 3 1006 7.99 3 10–11 5.87 3 10–10 1.25 3 1002 9.58 3 1003
19 rs12972970 1.28 3 10–15 1.78 3 10–16 9.96 3 1005 1.04 3 1006 7.83 3 10–11 5.94 3 10–10 1.25 3 1002 9.74 3 1003
19 rs12972156 2.31 3 10–15 3.03 3 10–15 6.72 3 1005 1.53 3 1006 1.21 3 10–10 1.10 3 10–09 9.26 3 1003 8.37 3 1003
3 rs9877502 1.68 3 1007 4.98 3 10–09 5.62 3 1007 7.24 3 1007 2.47 3 1007 4.39 3 10–08 4.60 3 1007 7.77 3 10–09
9 rs514716 2.99 3 10–09 1.07 3 10–08 4.14 3 1007 7.43 3 1007 3.76 3 10–08 1.38 3 10–08 2.00 3 10–08 2.30 3 1007
6 rs6922617 3.58 3 10–08 2.55 3 1005 2.34 3 1006 4.03 3 1004 3.49 3 1007 1.22 3 1004 1.66 3 1006 4.61 3 1005
aAge, gender, series, and PC are included in all the analyses as covariates. Bold numbers represent p values that pass the genome-wide significant
threshold.
Neuron
GWAS for CSF Tau LevelsMAF, and sample size. To determine whether the associations
seen with these three SNPs represent one signal or several inde-
pendent associations we analyzed the linkage disequilibrium be-
tween the SNPs and performed conditional analyses. When
rs6922617, rs6916710, or rs75932628 were included as a covar-
iate in themodel the other SNPs remained significant (Table 5). In
our population, none of these SNPs were in LD with each other
(Table S3 and additional information on https://hopecenter.
wustl.edu/data/Cruchaga_Neuron_2013). Together these results
suggest that these three SNPs are tagging three independent
signals within the TREM gene cluster that influence CSF ptau
levels, and at least in the case of TREM2-R47H, AD risk.
Conditional analysis was also performed for the other
genome-wide significant loci to test whether the association
signal at each locus is driven by a single effect or by multiple
independent effects and to determine whether the identified
loci interact with each other. For the other loci, the signal for
the conditioned SNP (and other SNPs in the same locus) totally
disappeared confirming that the association at each locus
represents a single signal. Conditioning on the genome-wide
significant SNPs did not dramatically change the signals in
other parts of the genome (additional information on https://
hopecenter.wustl.edu/data/Cruchaga_Neuron_2013), suggest-
ing that there is not strong interaction between these loci and
the rest of the genome.
To evaluate the specificity of these genome-wide significant
loci we also examined whether the SNPs were associated
with another AD biomarker, CSF Ab42 levels. Only SNPs within
the APOE region showed genome-wide association with
CSF tau and CSF Ab42 (rs2075650 p = 1.83 3 1040). For the
other regions, the p values for association with CSF Aß42 were
modest: 0.02 for rs9877502, 0.03, for rs514716, and for
3.6 3 103 rs6922617. Furthermore, the correlation between
the variants that give p values < 104 for either phenotype was
low (r2 = 0.07). Together these results confirm the specificity of
our results and that CSF tau/ptau and CSF Aß42 can be used
as endophenotypes to identify genetic variants that influence
different facets of the AD phenotype.260 Neuron 78, 256–268, April 24, 2013 ª2013 Elsevier Inc.Gene Expression Analysis
To further characterize these associations we evaluated gene
expression levels in three different ways. First, we determined
whether the expression levels of the identified genes are
associated with case-control status. Second, we determined
whether the SNPs associated with CSF tau/ptau levels also
affect tau (MAPT) gene expression levels in brain; and third,
we tested whether the SNPs were associated with expres-
sion levels of the candidate genes within each locus. To do
this, we analyzed MAPT, GEMC1, IL1RAP, OSTN, and FOXP4
gene expression using cDNA from the frontal lobes of 82 AD
cases and 39 nondemented individuals obtained through the
Knight-ADRC Neuropathology Core. In addition, MAPT, RFX3,
SLC1A1, and PPAPDC2 gene expression were analyzed using
publically available data from 486 late onset Alzheimer’s dis-
ease cases and 279 neuropathologically clean individuals form
the GSE15222 data set (Myers et al., 2007). We found strong
association for RFX3 (p = 1.39 3 109; b = 0.42), SLC1A1
(p = 1.01 3 104; b = 0.28), and PPAPDC2 (p = 4.80 3
103; b = 0.35), all located in the chromosome 9 region of as-
sociation, with case-control status. We also found a nominally
significant association of IL1RAP (Chr. 3; p = 0.04; b = 0.18)
with case-control status but not for MAPT, GLIS3, GEMC1,
OSTN, or FOXP4 (Table S5). None of the SNPs associated
with CSF tau/ptau levels showed an association with MAPT
gene expression levels suggesting that they impact CSF
tau levels by a post-transcriptional mechanism. Rs9877502
(chr. 3) showed nominally significant association with IL1RAP
expression (p = 0.02; b = 0.17), but not with other genes
in the same locus: GEMC1 (p = 0.54; b = 0.09), and OSTN
(p = 0.87; b = 0.02; Table S5).
Impact of the Identified Loci on Other AD Phenotypes
Because the purpose of this endophenotype-based approach is
to identify variants implicated in disease, we tested whether the
most significant SNP from each locus shows association with
risk for AD, tau pathology, or rate of cognitive decline. For the
SNP located on 3q28 between GEMC1 and OSTN, each copy
Figure 1. Genome-wide Signal Intensity
(Manhattan) Plots Showing the Individual p
Values (Based on Fixed-Effects Meta-anal-
ysis) against Genomic Position
The results for the association of CSF tau (top) and
ptau (bottom) levels with 5,815,690 SNPs are
shown. Within each chromosome, shown on the
x axis, the results are plotted left to right from the
p-terminal end. Horizontal dashed lines indicate
p value thresholds of 1 3 105 and 5 3 108
(genome-wide significance).
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GWAS for CSF Tau Levelsof the rs9877502-A allele (minor allele frequency [MAF] = 0.386)
is associated with higher CSF tau levels (regression coefficient
[b] = 0.052). Genotypes for rs9877502 were not available for
the case-control series, but rs1316356, which is in LD with
rs9877502 (D0 = 1, R2 = 0.932) showed a strong association
with AD risk (b = 0.81; p = 2.67 3 104). Further, in an indepen-
dent analysis leveraging two prospective cohorts, the Religious
Orders Study and Rush Memory and Aging Project, rs9877502
was associated with global cognitive decline (n = 1,593;
b = 0.014; p = 4.6 3 105), and in deceased subjects, this
variant was associated with burden of neurofibrillary tangles at
autopsy (n = 651; b = 0.055; p = 0.014) (Table 6). Importantly,
these associations showed the predicted direction of effect for
these phenotypes based on the CSF tau levels: the allele associ-
ated with lower tau levels is predicted to be protective for dis-
ease risk, associated with lower tau pathology, and with slower
cognitive decline.Neuron 78, 256–2There was also some evidence that the
SNPs associated with CSF tau and ptau
levels in the 6p21.1 locus are also associ-
ated with risk for AD. A rare (MAF = 0.01)
functional coding variant with large effect
size (odds ratio > 2) for AD risk was
recently reported (Guerreiro et al.,
2012). This rare SNP (TREM2-R47H,
rs75932628) was also associated with
CSF ptau levels at p = 2.6 3 103
(Table 4). For the other locus we failed
to detect significant association with
risk for AD, tau pathology or cognitive
decline, although the direction of the
effect was in the expected direction
based on the CSF levels (Table 6).
Pathway Analyses
We performed a pathway analysis to
determine whether signals that do not
achieve genome-wide significance (p <
1.0 3 1004) are enriched for sets of bio-
logically related genes, represented as
gene ontology terms (GO), and Kyoto
Encyclopedia of genes and genomes
(KEGG). Gene ontology terms for lipid
transport and metabolism are significant
for tau and ptau (Table S6). Furthermore,the KEGG pathway Type II diabetes mellitus is also significant for
ptau (enriched by MAPK9 and IRS2) and tau (enriched by
MAPK9, IRS2, and MAPK1). These results and the association
of genetic variants in GLIS3, implicated in diabetes, with CSF
tau levels support previous data suggesting that diabetes could
influence risk for AD.
DISCUSSION
We have previously shown that using CSF tau and ptau levels as
endophenotypes it is possible to identify genetic variants impli-
cated in AD (Kauwe et al., 2008, 2010, 2011; Cruchaga et al.,
2011, 2012). This study represents the largest GWAS for CSF
tau and ptau levels performed to date. Two other GWAS using
the ADNI data (n = 394) have been reported previously. In these
smaller studies only the APOE locus showed genome-wide sig-
nificant association with CSF Ab42 and tau levels. By using a68, April 24, 2013 ª2013 Elsevier Inc. 261
Figure 2. Regional Plots for Associations with CSF Tau and Ptau at Genome-wide Significance
Plots are centered on the most significant SNP at a given locus along with the combined-analysis results for SNPs in the region surrounding it (typically ± 400 kb).
Symbols are colored according to the LD of the SNP with the top SNP. The light blue line represents the estimated recombination rate. Gene annotations are
shown as dark green line. See also Tables S5 and S6.
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GWAS for CSF Tau Levelsthreefold larger sample size than these studies we were able
to identify four independent genome-wide significant loci,
including APOE (Table 2). We calculated that common variants
tagged by SNPs on the GWAS chip explain 6.45% and
15.14% of the overall variability in CSF ptau and tau levels,
respectively. The four genome-wide significant loci identified
in this study explain 1.45% of CSF ptau and 1.28% of CSF tau
variability (Table 3). Together these four loci explain 22% and
9% of the genetic component for CSF ptau and tau levels,
respectively, indicating additional variants and genes associated
with CSF tau and ptau levels may be identified in future, using
larger data sets and different approaches such as whole-
genome sequencing.
A single-stage GWAS, rather than a two stage GWAS
approach using the largest series as the discovery series, with
follow up of the most significant SNPs in the rest of the samples,
was used to maximize power (Dube´ et al., 2007; Rohlfs et al.,
2007; Kraft and Cox, 2008). There are several indications that
the identified genome-wide significant loci are real signals and
not artifacts from the analysis or type I errors. First, several
SNPs in each locus show highly significant p values (Figure 1),262 Neuron 78, 256–268, April 24, 2013 ª2013 Elsevier Inc.and at least one SNP in each locuswas directly genotyped (Table
2), eliminating the possibility that the signal is the result of an
imputation error. Second, each of the genome-wide significant
loci is the result of a strong and consistent association in each
data set. This is especially important, because a priori, the abso-
lute values for the CSF biomarker traits are significantly different
between series, which could lead to the identification of false
positives. The fact that the SNPs show similar effect sizes and
the same direction of effect in each data set indicates that we
were able to correct for any potential series-bias and represents
an internal replication of each of the associations. If we had
performed a two-stage analysis we would have identified these
same four loci. Finally, for three (chr. 19, APOE and 3q28 and
6p21.1) of the four genome-wide significant loci we also found
that the SNPs associated with CSF levels are also associated
with risk for disease, tau pathology, and/or cognitive decline.
Importantly, all of these associations are in the direction pre-
dicted by the CSF tau and ptau associations. The alleles associ-
ated with lower tau and ptau levels (which would be considered
protective) are associated with lower risk for AD, lower tangle
counts and slower memory decline.
Table 5. Association of the TREM2 Gene Cluster with CSF Tau and Ptau Levels
MAF n
Tau p Value (Beta) Ptau p Value (Beta)
Default
Model
Cond.
on R47H
Cond. on
rs6916710
Cond.
on rs6922617
Default
model
Cond.
on R47H
Cond.
on rs6916710
Cond.
on rs6922617
TREM2-R47H 0.01 815 6.9 3
104 (0.19)
— 1.3 3 103
(0.18)
5.3 3 104
(0.19)
2.6 3 103
(0.16)
— 4.7 3 103
(0.15)
2.0 3 103
(0.16)
rs6916710 0.39 815 8.2 3
103 (0.03)
0.015
(0.03)
— 9.3 3 103
(0.03)
6.4 3 103
(0.03)
0.011
(0.03)
— 7.0 3 103
(0.03)
rs6922617 0.06 815 4.1 3
105 (0.10)
3.2 3 105
(0.10)
4.6 3 105
(0.09)
— 6.1 3 106
(0.10)
4.9 3 106
(0.10)
6.5 3 106
(0.10)
—
The TREM2 R47H variant (rs75932628) was genotyped in the Knight-ADRC and ADNI series by Sequenom. The association of TREM gene cluster
variant with CSF levels was performed with PLINK including, age, gender, series, and principal component factors as covariates. See also Table S4.
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GWAS for CSF Tau LevelsAs in the previously published GWAS for CSF tau/ptau levels,
we found that the APOE locus was the strongest signal for CSF
tau and ptau (Han et al., 2010; Kim et al., 2011; Table 2). SNPs in
this locus explain between 0.25% and 0.29% of the variability in
CSF tau and ptau levels (Table 3). APOE is a known genetic risk
factor for AD and most functional studies have focused on
Ab-dependentmechanisms. To determinewhether or not the as-
sociation of APOE SNPs with CSF tau and ptau levels was
dependent of Ab pathology we performed analyses including
CSF Ab42 levels as a covariate. We also stratified our samples
by case control status and by low or high CSF Ab42 levels. In
all of these analyses, we found that the association between
APOE SNPs and tau or ptau levels remained significant (Table
4 and S2), suggesting that APOE may also affect tau pathology
via an Ab-independent mechanism. Several other studies sup-
port this hypothesis. APOE shows isoform specific differences
in its interaction with tau in vitro (Gibb et al., 2000; Zhou et al.,
2006), and in transgenic mice neuron-specific differences in
APOE isoform proteolysis are associated with increased tau
phosphorylation (Brecht et al., 2004) and pathology (Andrews-
Zwilling et al., 2010). These data provide additional evidence
that APOE could also influence risk for AD through a tau-depen-
dent mechanism, independent of effects on Ab. When APOE
genotype was included as a covariate, some SNPs in the
APOE locus showed a moderate association with CSF tau/
ptau levels (rs769449; p = 9.07 3 1003), indicating that most
of the association is driven by APOE genotype, but suggesting
that there may be additional variants in this region that modify
CSF tau levels and risk for AD, independently ofAPOE genotype.
SNPs within the 3q28 locus showed association with CSF
tau/ptau levels and a range of AD phenotypes including AD
risk in the case control data set, tangle pathology, and rate of
cognitive decline providing four independent sources of evi-
dence that variants in this region influence risk for AD through
a tau-dependent mechanism. Bioinformatic analysis did not
reveal any strong putative functional SNP. However, the genes
located in this region (GEMC1, OSTN and the noncoding RNA
SNAR-I, IL6RAP, UTS2D, and CCDC50) are highly expressed
in brain and involved in neuronal synaptogenesis (Yoshida
et al., 2012). The most significant SNP in this locus and 33
SNPs in LD with rs9877502 are located in transcription factor
binding sites and some of these SNPs are also part of a tran-
scription factor matrix (additional information on https://
hopecenter.wustl.edu/data/Cruchaga_Neuron_2013), suggest-ing that rs9877502 or a linked variant could influence the expres-
sion of one or more of the genes located in this region. Based on
the results of these bioinformatic analyses we performed several
gene-expression experiments. IL1RAP showed a nominally
significant association with case-control status (p = 0.04).
In addition rs9877502 showed a significant association with
IL1RAP expression in frontal cortex (p = 0.02; Table S5).
The lack of association with risk for AD in the ADGC GWAS for
the most significant SNP in the 6p21.1 locus may reflect insuffi-
cient power because the SNP has a low minor allele frequency
(MAF = 0.06). This hypothesis is supported by our recent identi-
fication of a rare functional coding variant (TREM2- R47H,
rs75932628) in the same locus which substantially increases
risk for AD (Guerreiro et al., 2012), and is also associated with
CSF ptau levels in the present study. Interestingly, the
genome-wide significant signal (tagged by rs6922617) is not in
LD with rs75932628. Conditional analyses in this region identi-
fied another independent SNP (Figure 2; Table 5), located in an
intron of TREML2 that is associatedwith CSF tau and ptau levels.
These data suggest that in this region there are at least three in-
dependent signals modifying CSF tau levels and risk for AD. Six
TREM-family genes (TREM1, TREM2, and TREML1 to TREML4)
are located in this region suggesting that several variants in
genes with similar function may affect risk for AD in an indepen-
dent manner. The genome-wide significant SNP in this locus
(rs11966476; p = 4.793 108), is located in a regulatory element
and could modify the expression of FOXP4, TREML3, TREML4,
or TREM1 (Figure 2). Unfortunately, these genes were not
included in the GSE15222 data set and Taqman assays for these
genes were out of the dynamic range sowewere unsuccessful in
analyzing expression levels in brain tissue. Despite this, data
from the Allen Brain Atlas suggests that these genes are
expressed in the brain. TREM2 was expressed at higher levels
in brain tissue from AD cases compared to controls (p =
1.35 3 105), as predicted in our previous studies (Guerreiro
et al., 2012).
For the 9p24.2 locus, we did not observe significant associa-
tion with risk for AD. This could be because these SNPs affect
another aspect of AD such as disease duration or age at onset.
Alternatively, these SNPs could affect CSF clearance or protein
half-life without affecting risk for AD. If this were the case, we
would expect that the same locus would be associated with
levels of other CSF proteins. To test this, we looked at the
association of all of the SNPs identified in this study at theNeuron 78, 256–268, April 24, 2013 ª2013 Elsevier Inc. 263
Table 6. Association of the Top Loci for CSF Tau and Ptau with Risk for AD, Tangle Counts, and Cognitive Decline
CSF (n = 1,269) Risk for AD (n = 22,771) Tangles (n = 651)
Global Cognitive
Decline (n = 1,593)
Chr. Rs # Phen. Minor Allele Beta p Value Beta p Value Beta p Value Beta p Value
19 rs2075650 tau G 0.074 4.29 3 1016 0.985 6.22 3 10184 0.266 9.33 3 1010 0.049 1.22 3 1011
ptau G 0.081 4.92 3 1016
3 rs9877502 tau A 0.052 4.98 3 1009 0.081* 2.67 3 10-04* 0.055 0.014 0.014 4.64 3 1005
ptau A 0.050 1.68 3 1007
9 rs514716 tau G 0.071 1.07 3 1008 0.022 0.518 0.036 0.360 0.004 0.479
ptau G 0.072 2.99 3 1009
6 rs6922617 tau A 0.094 2.55 3 1005 0.0174 0.677 0.029 0.547 0.007 0.330
ptau A 0.093 3.58 3 1008
The association of the most significant SNPs for CSF tau and ptau for risk for AD, tangle count, or cognitive decline is shown. p values and direction for
risk for disease were extracted from the previously published GWAS for AD (Naj et al., 2011). Association with tangle counts and memory decline was
performed in the Religious Orders Study (ROS) and the Rush Memory and Aging Project (MAP) as previously reported (De Jager et al., 2012; Keenan
et al., 2012). *The p value for risk for disease is for rs1316356, which is in high LD with rs9877502. In all cases the beta is calculated in reference to the
minor allele.
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GWAS for CSF Tau Levelsgenome-wide significance level with other CSF biomarkers. We
did not observe association between these SNPs and CSF levels
of either APOE or Ab (Cruchaga et al., 2012), suggesting that
these loci are specific for CSF tau levels and are not associated
with CSF clearance or protein half life in general. Finally, the lack
of association of these loci with AD risk could indicate that the
association with this locus is a type I error. The most significant
SNPs in this locus are located in intron 7 of GLIS3, a gene which
is highly expressed in brain. However, these SNPs (rs514716) are
not associated with GLIS3 expression in our relatively small
series of brain samples (82 AD cases and 39 nondemented indi-
viduals). Both common and rare variants in this gene have been
associatedwith risk for diabetes (Barker et al., 2011; Dimitri et al.,
2011). There are several studies linking AD with glucose
metabolism and diabetes (Accardi et al., 2012). In fact, a meta-
analysis combining data from eight studies, observed an associ-
ation between diabetes mellitus and increased risk for AD (OR:
1.51, 95%; CI = 1.31–1.73) (Bertram et al., 2013). In addition,
our pathway analysis independently identified a diabetes
pathway (path: hsa04930, p value for ptau = 6.60 3 1003, and
tau = 8.00 3 1004; Table S6), because of an enrichment of sig-
nificant SNPs in MAPK9, IRS2, and MAPK1. Two independent
analyses in this study therefore suggest that diabetes-related
genes may influence CSF tau and ptau levels, and ultimately
risk for AD. These data all provide supportive evidence for com-
mon variants in this locus that influence AD pathogenesis.
Finally, because SNPs identified in this study were associated
with CSF tau/ptau levels, we tested whether these SNPs are also
associated with MAPT gene expression. None of the genome-
wide significant SNPs showed association with MAPT expres-
sion in the brain and MAPT expression was not associated
with case-control status in our brain series, the GSE15222, or
any other published work on gene expression in brain (Webster
et al., 2009; Zou et al., 2012). These results suggest that the
SNPs identified in this study influence CSF tau/ptau protein
levels posttranscriptional mechanism. Tau protein undergoes
several posttranslational modifications including acetylation,
glycosylation; and phosphorylation. These changes are thought264 Neuron 78, 256–268, April 24, 2013 ª2013 Elsevier Inc.to play an important role in tau-related pathogenesis (Farı´as
et al., 2011; Marcus and Schachter, 2011). It is possible
that the genes identified in this study modify tau protein
levels through posttranslational modification rather than gene
expression.
Together these results clearly demonstrate the utility of using
these endophenotypes to identify AD risk variants and variants
associated with the rate of decline in symptomatic AD cases.
The use of these endophenotype allowed us to identify risk
variants that were not identified by GWAS because either those
variants did not pass the stringent multiple test correction
applied in the GWAS or were not covered in the earlier studies,
because of their relatively low MAF. A second advantage of
this approach is that in contrast to GWAS hits from case control
studies the endophenotype predicts a specific biological hy-
pothesis for the pathogenic effect, which can be directly tested.
In summary, we have detected four genetic loci associated
with CSF levels of tau, and ptau. One of them, inAPOE, is already
known to be associated with CSF tau and Ab42 (Kauwe et al.,
2007, 2008, 2011; Cruchaga et al., 2010, 2011) as well as risk
for AD. The other three are novel loci. The top hit for CSF tau
(rs9877502; 3q28) also exhibited association with risk for AD
(p = 2.673 104), tangle pathology (p = 0.01), and global memory
decline (p = 4.86 3 105). SNPs in the 6q21.1 locus are in the
TREM gene cluster close to TREM2, a gene in which a rare
variant has recently been reported to substantially increase risk
for AD (Guerreiro et al., 2012). The other genome-wide significant
locus identified in this study did not show associationwith risk for
disease, tangle pathology or memory decline. The lack of asso-
ciation with other AD phenotypes could be because these SNPs
have a weaker impact on these phenotypes, or because they
affect other aspects of AD, such as disease duration or age at
onset. Alternatively, the sample size for the data sets used in
the pathology and memory decline studies may not provide
enough statistical power. Overall, these results illustrate how ge-
netic studies of disease endophenotypes are an effective
approach for identifying disease risk loci that is complementary
to case-control association studies.
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Subjects and Phenotypes
CSF tau, ptau, and Ab42 were measured in 1,269 individuals. There were 501
samples from research participants enrolled in longitudinal studies at the
Knight-ADRC, 394 in ADNI, 323 in studies at the University of Washington
(UW), and 51 in studies in University of Pennsylvania (UPenn). CSF collection
and Ab42, tau, and ptau181 measurements were performed as described
previously (Fagan et al., 2006). Table 1 shows the demographic data and
description of the CSF biomarkers in each data set. The samples were geno-
typed using Illumina chips. Cases received a diagnosis of dementia of the
Alzheimer’s type (DAT), using criteria equivalent to the National Institute of
Neurological and Communication Disorders and Stroke-Alzheimer’s Disease
and Related Disorders Association for probable AD (McKhann et al., 1984).
Controls received the same assessment as the cases but were nondemented.
All individuals were of European descent and written consent was obtained
from all participants.
While there are differences in the absolute levels of the biomarker measure-
ments between the studies that likely reflect differences in the methods used
for quantification (regular ELISA versus Luminex), ascertainment, and/or in
handling of the CSF after collection, CSF ptau levels in the Knight-ADRC,
ADNI, UW, and UPenn samples show similar characteristics (Table S1). CSF
ptau and tau show a 10-fold difference between individuals in each data set
and have similar covariates in each data set.
The Religious Orders Study (ROS) and the Rush Memory and Aging Project
(MAP) recruit participants without known dementia who agree to annual
clinical evaluations and sign an Anatomic Gift Act donating their brains at
death. The full cohort with genotype data included 1,708 subjects (817 ROS
and 891 MAP). The mean age at enrollment was 78.5 years and 30.9% were
male. At the last evaluation, 24.9% met clinical diagnostic criteria for AD and
21.8% had mild cognitive impairment. The summary measure of global cogni-
tive performance was based on annual assessments of 17 neuropsychiatric
tests. A nested autopsy cohort consisted of 651 deceased subjects (376
ROS and 275 MAP); mean age at death was 81.5 years and 37.6% were
male. Proximate to death, 40.9% of subjects included in the autopsy cohort
met clinical diagnostic criteria for AD. Bielschowsky silver stain was used to
visualize neurofibrillary tangles in tissue sections from the midfrontal, middle
temporal, inferior parietal, and entorhinal cortices, and the hippocampal CA1
sector. A quantitative composite score for neurofibrillary tangle pathologic
burden was created by dividing the raw counts in each region by the standard
deviation of the region specific counts and then averaging the scaled counts
over the five brain regions to create a single standardized summary measure.
Additional details of the ROS and MAP cohorts as well as the cognitive and
pathologic phenotypes are described in prior publications (De Jager et al.,
2012; Keenan et al., 2012).
Genotyping
The Knight-ADRC and UW samples were genotyped with the Illumina 610 or
the Omniexpress chip. The ADNI samples were genotyped with the Illumina
610 chip, and the UPenn sample with the Omniexpress. Prior to association
analysis, all samples and genotypes underwent stringent quality control
(QC). Genotype data were cleaned by applying a minimum call rate for SNPs
and individuals (98%) and minimum minor allele frequencies (0.02). SNPs
not in Hardy-Weinberg equilibrium (p < 1 3 106) were excluded. The QC
cleaning steps were applied for each genotyping array separately. We tested
for unanticipated duplicates and cryptic relatedness among samples using
pairwise genome-wide estimates of proportion identity-by-descent. When a
pair of identical samples or a pair of samples with cryptic relatedness was
identified, the sample from the Knight-ADRC or samples with a higher number
of SNPs passing QCwere prioritized. Eigenstrat (Price et al., 2006) was used to
calculate principal component factors for each sample and confirm the
ethnicity of the samples. Rs7412 and rs429358 which define the APOE
ε2/ε3/ε4 isoforms were genotyped using Taqman genotyping technology, as
previously described (Koch et al., 2002; Cruchaga et al., 2009, 2010, 2011,
2012; Kauwe et al., 2010).
DNA fromROS andMAP subjects was extracted fromwhole blood, lympho-
cytes, or frozen postmortem brain tissue and genotyped on the AffymetrixGenechip 6.0 platform, as previously described (Keenan et al., 2012).
Following standard QC procedures, imputation was performed using
MACH software (version 1.0.16a) and HapMap release 22 CEU (build 36) as
a reference.
Imputation in Illumina Data Sets
The 1,000 genome data (June 2011 release) and the Beagle software were
used to impute up to 6 million SNPs. SNPs with a Beagle R2 of 0.3 or lower,
a minor allele frequency (MAF) lower than 0.02, out of Hardy-Weinberg equilib-
rium (p < 1 3 106), a call rate lower than 95% or a Gprobs score lower than
0.90 were removed. A total of 5,815,690 SNPs passed the QC process. To
confirm the accuracy of our imputation we genotyped 23 SNPs, included the
most significant SNPs, using Sequenom. All of the SNPs, showed a con-
cordance rate between imputed and directly genotyped calls greater than
97.9% except rs1024718 which was 93.33% (Table S7).
Statistical Analyses
Association of CSF ptau with the genetic variants was analyzed as previously
reported (Cruchaga et al., 2010, 2011; Kauwe et al., 2011). Our analysis
included a total of 5,815,690 imputed and genotyped variants. CSF tau and
ptau values were log transformed to approximate a normal distribution.
Because the CSF biomarker levels were measured using different platforms
(Innotest plate ELISA versus AlzBia3 bead-based ELISA, respectively), we
were not able to combine the raw data. For the combined analyses we stan-
dardized the mean of the log transformed values from each data set to zero.
No significant differences in the transformed and standardized CSF values
for different series were found.
We used Plink to analyze the association of SNPswith CSF biomarker levels.
Age, gender, site, and the three principal component factors for population
structure were included as covariates. The calculated genomic inflation factor
was l = 1.003, and 1.009, for tau and ptau, respectively (Figure S1). In order to
determine whether the association of APOE with CSF tau levels was driven by
case-control status, we included clinical dementia rating (CDR) or CSF Ab42 as
a covariate in the model or stratified the data by case control status. We also
performed analyses including APOE genotype and CDR as covariates.
Association with Risk for Alzheimer’s Disease
p values for the most significant SNPs for the association with CSF tau and
ptau were included here from the previously published GWAS for AD, consist-
ing of 11,840 controls and 10,931 cases (Naj et al., 2011).
Genome Partitioning
We used the algorithm GCTA (genome-wide complex trait analysis) to
estimate the proportion of phenotypic variance explained by genome-wide
and imputed SNPs (Yang et al., 2011).
Association with Cognitive Decline and Neurofibrillary Pathology
Analyses of SNP effects on global cognitive decline in ROS andMAPwere per-
formed as in prior publications (De Jager et al., 2012). Briefly, we first fit linear
mixed effects models using the global cognitive summary measure in order to
characterize individual paths of change, adjusted for age, sex, years of educa-
tion, and their interactions with time. At least two longitudinal measures of
cognition were required for inclusion in these analyses, for which data on
1,593 subjects was available. We then used these person-specific, residual
cognitive decline slopes as the outcome variable in our linear regression
models, with each SNP of interest coded additively relative to the minor allele,
and further adjusted for study membership (ROS versus MAP) and the first
three principal components from population structure analysis. For analyses
of neurofibrillary tangle burden, linear regression was used to relate SNPs to
the pathologic summary measure, adjusting for age at death, study member-
ship, and three principal components. Because the data were skewed,
square-root of the scaled neurofibrillary tangle burden summary score was
used in analyses.
Bioinformatics Analyses
We used Pupasuite (Conde et al., 2006), the SNP Function Portal (http://
brainarray.mbni.med.umich.edu/Brainarray/Database/SearchSNP/), the SNPNeuron 78, 256–268, April 24, 2013 ª2013 Elsevier Inc. 265
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Database/SearchSNP/snpfunc.aspx), and the SNP and CNV Annotation Data-
base (http://www.scandb.org) to perform the SNP annotation and to identify
the putative functional SNPs.
Pathway Analysis
We applied the method ALIGATOR (Holmans et al., 2009) to identify the gene
ontology (GO) terms and Kyoto Encyclopedia of Genes and Genomes (KEGG)
pathways enriched by SNP with significant association. This method performs
an overrepresentation analysis, evaluating the significance for each category
of genes while correcting for gene size, number of SNPs genotyped per
gene, overlapping genes, and linkage disequilibrium between SNPs. It selects
the set of genes, which are tagged by SNPs that are more significant than a
specific threshold (p values < 1.0E-04). The pruning process that eliminates
SNPs in linkage disequilibrium is performed by considering only the most sig-
nificant SNP among all of the SNPs that have r2 > 0.2 and are within 1 Mb.
Moreover, we removed all of the genes that are in the APOE region (1 Mb
up/downstream) (Jones et al., 2010). The significance of each term and
pathway is calculated by comparing the number of significant genes to the
number of genes expected by chance. For this purpose, the algorithm gener-
ates 5,000 sets of genes, by randomly selecting SNPs until a list of n tagged
genes is formed. The excess of significantly overrepresented sets of genes
(Holmans et al., 2009) is calculated by applying a bootstrap method (1,000
permutations).
Gene Expression Analysis
Analyses of association between SNPs and gene expression was carried out
using cDNA from the frontal lobes of 82 AD cases and 39 nondemented indi-
viduals obtained through theWashington University Knight-Alzheimer Disease
Research Center (WU-ADRC) Neuropathology Core. Total RNA was extracted
from the frontal lobe using the RNeasy mini kit (QIAGEN) following the manu-
facturer’s protocol. cDNAs were prepared from the total RNA, using the High-
Capacity cDNA Archive kit (ABI). Gene expression was analyzed by real-time
PCR, using an ABI-7500 real-time PCR system. Real-time PCR assays were
used to quantify MAPT, GLIS3, GEMC1, IL1RAP, OSTN, and FOXP4 cDNA
levels using Taqman assays. GADPH, MAP2, AIF, and GFAP were used as
reference genes. Each real-time PCR run included within-plate duplicates.
Real-time data were analyzed using the comparative Ct method. The Ct values
of each sample were normalized with the Ct value for the housekeeping genes.
We also used the GEO data set GSE15222 (Myers et al., 2007) to analyze the
association ofMAPT, RFX3, SLC1A1, and PPAPDC2 genes and case-control
status. None of the other genes (GLIS3,GEMC1, IL1RAP,OSTN, FOXP4) were
found in this data set. This data set includes genotype and expression data
from 486 late onset Alzheimer’s disease cases and 279 neuropathologically
clean individuals. Association of mRNA levels with case control status or the
different SNPs was carried out using ANCOVA. Stepwise regression analysis
was used to identify the potential covariates (postmortem interval, age at
death, site, and gender) and significant covariates were included in the
analysis. SNPs were tested using an additive model with minor allele homozy-
gotes coded as 0, heterozygotes coded as 1, and major allele homozygotes
coded as 2.
ADNI Material and Methods
Data used in the preparation of this article were obtained from the ADNI
database (www.loni.ucla.edu/ADNI). The ADNI was launched in 2003 by the
National Institute on Aging, the National Institute of Biomedical Imaging and
Bioengineering, the Food and Drug Administration, private pharmaceutical
companies, and nonprofit organizations, as a $60 million, 5 year public-private
partnership. The Principal Investigator of this initiative is Michael W. Weiner,
MD. ADNI is the result of efforts of many coinvestigators from a broad range
of academic institutions and private corporations, and subjects have been
recruited from over 50 sites across the US and Canada. The initial goal
of ADNI was to recruit 800 adults, ages 55 to 90, to participate in the
research—approximately 200 cognitively normal older individuals to be
followed for 3 years, 400 people with MCI to be followed for 3 years, and
200 people with early AD to be followed for 2 years. For up-to-date information,
see www.adni-info.org.266 Neuron 78, 256–268, April 24, 2013 ª2013 Elsevier Inc.SUPPLEMENTAL INFORMATION
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